Pharmaceuticals News and Research

RSS

Prescription drugs expensive in Australia and likely to increase

According to experts Australians are facing some of the highest ‘out-of-pocket’ costs in the industrialized world for prescription medicines and the problem is likely to worsen

14 Sep 2011

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.

14 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.

14 Sep 2011

Kremers Urban reaches settlement agreement with ALZA over Concerta patent litigation

Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product. The ANDA is currently under review with FDA.

14 Sep 2011

Combining cell biology and molecular genetics for single-cell research

Fluidigm Corporation has announced a collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), to co-host a public seminar series on the isolation and analysis of single cells. Entitled 'A Powerful Technique for Single-Cell Analysis', the public seminar series will showcase cell isolation using the BD FACSAria™ III Cell Sorter and analysis using the Fluidigm BioMark™ HD System.

13 Sep 2011

AM-Pharma announces €29.2m series D round of financing

AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing.

13 Sep 2011

BGI, Merck collaborate to focus on biomarkers and genomic technologies

Merck, known as MSD outside the United States and Canada, and BGI, the world's largest genomics center, announced today that they have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies.

13 Sep 2011

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

13 Sep 2011

Hawthorn, CoPlex Therapeutics sign licensing deal to develop and commercialize hawAD14 for Alzheimer's

Hawthorn Pharmaceuticals, Inc. announced today an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

13 Sep 2011

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Researchers identify glucokinase triggers beta cell regeneration in pancreas

Researchers at the Hebrew University of Jerusalem have identified the key signal that prompts production of insulin-producing beta cells in the pancreas -- a breakthrough discovery that may ultimately help researchers find ways to restore or increase beta cell function in people with type 1 diabetes.

12 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

PHT announces availability of eDHP-18 QoL questionnaire on all ePRO collection modalities

PHT Corporation announced today the availability of the electronic version of the DHP-18 (Diabetes Health Profile) Quality of Life (QoL) questionnaire on all of its electronic patient reported outcome (ePRO) collection modalities - smartphone, tablet and Web. PHT is the global pacesetter in PRO and ePRO solutions that maximize the collection of high-quality data from clinical trial patients to improve clinical trial efficiencies.

12 Sep 2011

IBN scientists harness ultrasmall peptides to repair spinal disc damage

New ultrasmall peptides that can be used as building blocks for a wide range of regenerative applications such as spinal disc replacement and cartilage repair have been developed by scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute. These peptides spontaneously assemble in water to form hydrogels, which resemble collagen, a major component of connective tissues found in cartilage, ligaments, tendons, bone and skin.

12 Sep 2011

USC team produces world's first high-resolution images of α7 neuroreceptor

For the first time, USC scientists have mapped out a neuroreceptor. This scientific breakthrough promises to revolutionize the engineering of drugs used to treat ailments such as Alzheimer's disease and schizophrenia.

12 Sep 2011

Pew Health Group to ensure safety of U.S. drug supply

On Wednesday, September 14, Allan Coukell, a pharmacist and director of medical programs at the Pew Health Group, will testify before the Senate Health Education Labor and Pensions Committee about the need for Congressional action to ensure the safety of the U.S. drug supply.

12 Sep 2011